第二代5-HT3受体拮抗剂——帕洛诺司琼的研究进展  

Development in Research of Second-generation 5-HT3 Antagonist-Palonosetron

作　　者：臧鸿斌[1] 张琼予[1] 贺薇[1] 腾赞[2] 

机构地区：[1]中国医科大学,临床七年制沈阳110001 [2]中国医科大学附属第一医院肿瘤内科,沈阳110001

出　　处：《医学综述》2010年第16期2491-2493,共3页Medical Recapitulate

摘　　要：自5-羟色胺3(5-HT3)受体拮抗剂于20世纪90年代问世以来,化疗中急性呕吐得到有效控制,但延迟呕吐的控制效果仍不理想。现在,第二代5-HT3受体拮抗剂——帕洛诺司琼已经被应用于临床,经观察证实其能显著提高延迟呕吐的控制效果。但如何预防延迟呕吐,特别是多天、大计量化疗中如何预防呕吐仍然是困扰肿瘤化疗的难题。本文旨在介绍帕洛诺司琼的临床研究结果,包括其对于控制延迟呕吐的良好效果;在多天、大剂量化疗中,其预防呕吐的效果;其独特的分子学特性及未来关于该药物的研究方向。5-HT3 antagonists have been in use in clinical practice since 1990s.From then on,the control of acute vomiting has improved a lot,but the control of delayed vomiting is not acceptable,remaining as an open problem.Recently,the second-generation 5-HT3 antagonist,palonosetron,has been extensively used in clinical practice,which has proved to be effective in the control of delayed vomiting.However,the effectiveness of palonosetron in multiple-day and high-dose chemotherapy has yet to be justified.This article aims to describe the progress of the researches on palonosetron,including its effectiveness in the prevention of delayed vomiting,the effectiveness of prevention of acute and delayed vomiting in multiple-day and high-dose chemotherapy,the specific molecular characteristics,and the future development of palanosetron.

关 键 词：化疗相关恶心呕吐 5-羟色胺3受体拮抗剂 帕洛诺司琼 受体内化 

分 类 号：R975.4[医药卫生—药品] R730.5[医药卫生—药学]